Enhanced Belimumab Results in BLISS-LN Subgroup Analysis
Автор: Nephrology Times
Загружено: 2025-06-06
Просмотров: 152
Описание:
#nephrology #lupus #lupusnephritis #belimumab
New data presented at the 16th International Congress on Systemic Lupus Erythematosus (LUPUS 2025) highlighted the efficacy and safety of belimumab for active proliferative lupus nephritis (LN). The findings, from a post hoc subgroup analysis of the BLISS-LN trial, demonstrated enhanced renal responses with belimumab compared with placebo at weeks 76 and 104 among patients with active class 3 or 4 LN plus or minus concomitant class 5 receiving mycophenolate mofetil (MMF). Lead investigator Richard Furie, MD, discussed the study with Nephrology Times.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
